PCORI Answers Critical Questions
Patient: I’m over 55 and my MS has been stable for years. Should I stay on my disease-modifying drug or consider a different treatment?
Clinician: In my rural community, would telerehabilitation be as effective as in-clinic rehabilitation? Would it provide a good option for patients without easy access to MS specialty centers?
Patient: Which of the available medications work best to treat my fatigue?
Multiple Sclerosis Study Spotlights
This study compares how well two disease-modifying medicines, fingolimod and dimethyl fumarate, prevent relapses in patients with the relapsing-remitting form of MS.
A PCORI-funded study asks whether some older patients can safely stop taking medicines to treat the relapsing-remitting form of MS. Though effective, these medicines are expensive and have side effects.
Clinics that provide exercise, yoga, and other nondrug therapies are scarce in rural and low-income areas. This study compares the benefits of an exercise program when patients receive it in a clinic versus at home via internet or telephone.